NCT07297797

Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-9563 in Patients With Mild to Moderate Hypertension

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 234 (estimated)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.

Conditions

• Mild to Moderate Hypertension

Interventions

Type	Name	Description
DRUG	HRS-9563 Injection	HRS-9563 Injection
DRUG	sodium chloride injection	sodium chloride injection

Timeline

• Start date: 2026-01-14
• Primary completion: 2026-07-01
• Completion: 2027-10-01
• First posted: 2025-12-22
• Last updated: 2026-01-26

Locations

1 site across 1 country: China